- A must-attend and rapidly growing event with experts around the world: 36 speakers from 10 countries
- In-depth scientific review of the role played by the HERVs in a broad range of diseases including multiple sclerosis, amyotrophic lateral sclerosis and cancer
- Focus on positive Phase 2 clinical trial results with GeNeuro’s temelimab through presentation by PD Dr. David Kremer, Heinrich-Heine-University of Düsseldorf, Germany
Geneva, Switzerland, October 31, 2019 – 7:30 am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, such as multiple sclerosis (MS) and type-1 diabetes, announced that the company will present at and sponsor the 3rd HERVs & Disease International Workshop on Human Endogenous Retroviruses and Diseases, to be held November 5-6, 2019, in Lyon, France.
For more information :